Valuation ORIC Pharmaceuticals, Inc. Börse Stuttgart
Stocks
4TZ
US68622P1093
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
16:30:39 24/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 12.23 EUR | +1.48% |
|
+1.77% | +74.71% |
Company Valuation: ORIC Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 578.9 | 264.8 | 501.9 | 569.5 | 796.6 | 1,472 | - | - |
| Change | - | -54.26% | 89.55% | 13.47% | 39.89% | 84.76% | - | - |
| Enterprise Value (EV) | 578.9 | 264.8 | 266.8 | 569.5 | 751 | 1,472 | 1,472 | 1,472 |
| Change | - | -54.26% | 0.78% | 113.42% | 31.87% | 95.99% | 0% | 0% |
| P/E | -7.1x | -2.62x | -4.69x | -4.41x | -5.56x | -9.35x | -8.63x | -7.67x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | 0.4x | 0.66x | 0.3x | -2.85x | -1.02x | -0.6x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 480x |
| EV / Revenue | - | - | - | - | - | - | - | 480x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -9.12x | -8.89x | -10.3x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -8.26x | -7.22x | -6.17x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -10.8x | -8.71x | -6.75x |
| FCF Yield | -10.4% | -29.2% | -17.2% | -20% | -14% | -9.24% | -11.5% | -14.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | -1.518 | -1.646 | -1.852 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 3.064 |
| EBITDA 1 | -77.97 | -90.8 | -109.7 | -141.8 | -141.8 | -161.4 | -165.6 | -143 |
| EBIT 1 | -78.87 | -91.77 | -110.8 | -142.9 | -143 | -178.2 | -203.9 | -238.7 |
| Net income 1 | -78.72 | -89.12 | -100.7 | -127.8 | -129.5 | -165.6 | -196.9 | -239.6 |
| Net Debt | - | - | -235 | - | -45.67 | - | - | - |
| Reference price 2 | 14.70 | 5.89 | 9.20 | 8.07 | 8.18 | 14.20 | 14.20 | 14.20 |
| Nbr of stocks (in thousands) | 39,382 | 44,953 | 54,552 | 70,567 | 97,389 | 103,653 | - | - |
| Announcement Date | 3/21/22 A | 3/16/23 A | 3/11/24 A | 2/18/25 A | 2/23/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.45x | 7.54x | 15.37x | 1.38% | 72.12B | |
| 37.53x | 9.72x | 29.82x | 0.04% | 65.85B | |
| -18.08x | 7.59x | -9.85x | -.--% | 29.28B | |
| -79.5x | 14.86x | -71.64x | -.--% | 27.47B | |
| 33.76x | 6.66x | 17.64x | -.--% | 26.7B | |
| 27.2x | 5.1x | 17.12x | -.--% | 20.06B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.22B | |
| 2460.33x | 41.28x | -5047.29x | -.--% | 16.4B | |
| 16.73x | 4.96x | 11.58x | -.--% | 13.4B | |
| Average | 283.59x | 13.03x | -555.29x | 0.19% | 32.17B | |
| Weighted average by Cap. | 153.01x | 11.04x | -277.31x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORIC Stock
- 4TZ Stock
- Valuation ORIC Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
